537 results on '"Dayan, Colin M."'
Search Results
2. Age-related variation in thyroid function – a narrative review highlighting important implications for research and clinical practice
3. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
4. Maternal type 1 diabetes and relative protection against offspring transmission
5. Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study
6. General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study).
7. Controlled Antenatal Thyroid Screening Study III: Effects of gestational thyroid status on adolescent brain morphology
8. Author Correction: A perspective on treating type 1 diabetes mellitus before insulin is needed
9. Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides
10. Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes
11. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis
12. Evidence for C-peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
13. Editorial: (Re)defining hypothyroidism: the key to patient-centered treatment
14. Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype
15. Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study
16. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy
17. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study
18. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
19. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
20. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans
21. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial
22. Formulation of hydrophobic peptides for skin delivery via coated microneedles
23. Should radioiodine now be first line treatment for Graves’ disease?
24. Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes
25. Global epidemiology of hyperthyroidism and hypothyroidism
26. What does the licensing of teplizumab mean for diabetes care?
27. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans
28. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes
29. Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial.
30. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
31. sj-docx-1-mso-10.1177_20552173221142741 - Supplemental material for Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
32. The Race for New Treatments for Graves Orbitopathy (Thyroid Eye Disease).
33. Educational Attainment and Childhood-Onset Type 1 Diabetes
34. Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189–2201
35. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes
36. Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data
37. Diagnosing Type 1 diabetes in adults:Guidance from the UK T1D Immunotherapy consortium
38. Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes.
39. Immunotherapy and Prevention of Autoimmune Endocrinopathies
40. Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis
41. Relationship between thyroid hormones and metabolic syndrome in a normal thyroid function population in Western China
42. An Invitation to Join the Consortium on Thyroid and Pregnancy
43. Paradoxical Relationship Between Body Mass Index and Thyroid Hormone Levels: A Study Using Mendelian Randomization
44. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta‐analysis
45. General population screening for childhood type 1 diabetes: is it time for a UK strategy?
46. Insights From Single Cell RNA Sequencing Into the Immunology of Type 1 Diabetes- Cell Phenotypes and Antigen Specificity
47. Radioiodine and Thyroid Eye Disease
48. Radioiodine and Thyroid Eye Disease: Use with Caution
49. Management of patients with Graves’ orbitopathy: initial assessment, management outside specialised centres and referral pathways
50. β-Cell–Specific CD8 T Cell Phenotype in Type 1 Diabetes Reflects Chronic Autoantigen Exposure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.